Since liver involvement in patients with metastatic cancer has limited options and poor outcomes, we conducted a phase I study to determine the safety, activity and pharmacokinetic characteristics of hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Cohorts of three patients having predominant hepatic metastases received HAI nab-paclitaxel at three dose levels ( given for 1 hour every 3 weeks, the treatment was well tolerated and showed activity in advanced cancer patients with predominant liver metastases.
ABSTRACT
Since liver involvement in patients with metastatic cancer has limited options and poor outcomes, we conducted a phase I study to determine the safety, activity and pharmacokinetic characteristics of hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Cohorts of three patients having predominant hepatic metastases received HAI nab-paclitaxel at three dose levels (180 mg/m given for 1 hour every 3 weeks, the treatment was well tolerated and showed activity in advanced cancer patients with predominant liver metastases.
INTRODUCTION
The liver is a common site of metastatic involvement in patients with gastrointestinal, breast, ovarian, cervical, melanoma, and other solid tumors, often the predominant site of metastatic disease (1, 2) . Except for a minority of patients with resectable isolated hepatic lesions, the overall prognosis for patients with malignant tumors involving the liver is dismal (3) . Because liver metastases derive their blood supply from the hepatic artery, unlike hepatocytes, which are perfused predominantly from the portal vein (4), hepatic arterial infusion (HAI) of a therapeutic agent has been explored as a treatment strategy for patients with unresectable liver metastases. Direct infusion of a therapeutic agent by HAI produces higher drug concentrations at the tumor site, while circumventing high-dose, chemotherapy-related systemic side effects to normal tissue(5).
Different agents have been used to treat hepatic metastasis from various tumor types: cisplatin (6-9), oxaliplatin (10) (11) (12) (13) (14) , paclitaxel (15, 16) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) might be more suitable than paclitaxel for HAI because of the ability to deliver more drug over a shorter frame of time and greater extent of tissue distribution as a result of a greater first-pass hepatic extraction (31) (32) (33) .In a pilot study assessing the feasibility, maximum tolerated dose Table 1 ). The second part was a dose expansion phase designed to enroll additional patients treated at the MTD or dose level 3 if the MTD was not defined. The MTD was defined as the highest dose level at which six patients were treated with < 1 patient experiencing a DLT occurring during the first 4 weeks. A hematologic DLT was defined as platelets < 25,000/mm Statistical analyses were carried out using GraphPad Prism (San Diego, CA) and a pvalue < 0.05 was considered statistically significant.
Treatment and Dose Adjustment
After completing the informed consent process and registration, eligible patients were admitted after consultation with the interventional radiology service. On the day of treatment, patients underwent angiographic placement of the catheter for HAI.
Arteriography (using non-iodinated contrast media) of the celiac axis and superior mesenteric artery was performed to delineate anatomy, identify accessory arteries, and confirm adequacy of portal venous flow and adequate positioning of the catheter. If indicated, embolization was done to alter collateral blood flow patterns or to protect gastrointestinal organs (36) . After catheter placement, patients were taken to the nuclear medicine department for a catheter flow study. Once patients were transported to the designated floor, treatment was initiated with the assigned dose of nab-paclitaxel plus 1500 IU of heparin intraarterially over 60 minutes without prophylactic medications. The hepatic intraarterial catheter was removed once the intraarterial infusion was completed.
The treatment was repeated once every 3 weeks.
To be eligible to participate in a subsequent treatment cycle, patients had to meet minimum retreatment criteria, including an ANC > 1500/mm In general, anemia was not an indication for dose reduction. Patients who experienced ≥ grade 3 thrombocytopenia and/or neutropenia had a dose reduction of 25% and prophylactic granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) were used in subsequent cycles. Grade 3 or greater neuropathy required interruption of nab-paclitaxel until adverse effects resolved. Grade 2 neuropathy or other ≥ grade 3 non-hematologic toxicities resulted in a 25% dose reduction in subsequent cycles. Abnormal hepatic enzyme values alone did not require dose reduction.
Pharmacokinetic Studies
Pharmacokinetic comparison studies were performed for patients enrolled in the dose escalation phase. Two sets of pharmacokinetic studies were performed to compare peak drug concentrations and systemic drug exposure of IV and HAI nab-paclitaxel, both given over 60 minutes. 
RESULTS

Patient Characteristics
A total of 38 patients (median age, 61 years; range, 38 to 77 years) who met the inclusion and exclusion criteria were recruited into the study, as described in Table 1 .
These patients had metastatic breast cancer (n=12 patients), colorectal cancer (n=8 patients), melanoma (n=4 patients), esophageal cancer (n=3 patients), cholangiocarcinoma (n=3 patients), ovarian cancer (n=2 patients), sarcoma (n=2 patients) and one patient each with cervical, pancreatic, prostate cancer, angiosarcoma, leiomyosarcoma, and carcinoid tumor (n=6 patients). All 38 patients were evaluable for toxicity. All 38 patients were considered evaluable for response, including 26 patients who were evaluable by RECIST criteria as shown in Figure 1 . Eight patients showed clinical progression, two patients received 1 cycle of the treatment with early withdrawal for hospice care, and two patients died, as described below. These patients were considered treatment failures.
Toxicity
No DLTs were observed in the 38 patients evaluable for toxicity. The most common adverse events included alopecia and fatigue. One patient with metastatic colorectal cancer was admitted for neutropenic fever on day 8 of cycle 1 at dose 260 mg/m grade toxicities included rash, nausea, vomiting, diarrhea, mucositis, hematuria, neutropenia and thrombocytopenia, as shown in Table 2 .
Antitumor Activity
Among 38 patients, four patients withdrew after 1 cycle of treatment because of rapid tumor progression and/or adverse events. Three patients had SD > 4 months (7.9%).
Two patients (1/12 breast cancer, and 1/1 cervical cancer) achieved PR (5.3%) as shown in Figure 2 , lasting for 5 months and 15 months, respectively. Another patient with metastatic esophageal carcinoma had liver lesions successfully resected after 10 cycles of HAI nab-paclitaxel, achieving tumor reduction by 11%. This patient showed no evidence of disease with the latest follow-up at 12 months post-surgery.
Pharmacokinetic Studies
Pharmacokinetic analyses were conducted to determine whether hepatic extraction of nab-paclitaxel administered through HAI was greater than that from IV nab-paclitaxel when HAI nab-paclitaxel was administered over a one-hour period of time.
The results of this trial provide several interesting observations. First, HAI nab-paclitaxel can be given safely at doses up to 260 mg/m 2 , which is the maximum FDA approved IV dose. Second, there is approximately a 42% hepatic extraction for nanoparticle albuminbound paclitaxel. Third, since an MTD was not defined, it is possible that raising the dose further is feasible and safe. We plan to explore whether prolonged HAI nabpaclitaxel might result in higher hepatic extraction because the hepatic uptake achieved Clinical data showed that Cmax and AUC were well correlated with toxicities (42) . When the pharmacokinetic data of HAI nab-paclitaxel were compared with those from IV nabpaclitaxel, Cmax and AUC were reduced by more than 50% in patients who received HAI nab-paclitaxel. These data suggest that higher doses of HAI nab-paclitaxel might be safer than the FDA approved IV dosages, and are consistent with the notion that the Cmax and AUC of IV nab-paclitaxel are correlated with clinical toxicities. Of course, the lower systemic exposure could also attenuate response in non-hepatic sites, hence supporting the idea that further increasing the dose of HAI nab-paclitaxel or combining it with systemic agents should be studied. via caveolae (43) (44) (45) , and then into tumor cells mediated by secreted protein acidic rich in cysteine (SPARC) (46) . Previous studies showed that administration of paclitaxel directly into the hepatic artery resulted in a 95% mean hepatic extraction during the infusion and a 61% mean extraction from 5 to 9 hours after completion of the infusion (16, 47) . In contrast, this trial demonstrated approximately a 42% mean hepatic extraction following HAI of nab-paclitaxel when administered over a 60-minute period of time. The moderate hepatic extraction rate associated with HAI nab-paclitaxel over 60 minutes could be explained by the short infusion time, saturating SPARC-mediated intracellular uptake of nab-paclitaxel (48, 49) . Accumulating evidence indicates that constitutive activation of multiple signaling pathways in cancer cells requires a multitargeted approach for optimal results. Therefore, it is likely that HAI nab-paclitaxel will need to be combined with other therapeutic agents to optimize therapeutic effects.
Finally, because it is well tolerated with an excellent safety profile, further study with increased dosages of HAI nab-paclitaxel, and prolonged infusion times to increase hepatic extraction as well as its combination with other agents is planned. 
